GlassScriptPhysician profile
Benjamin N Wasserman
NPI 1588275226
$791.83
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $792.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $288.03 | 2022 | |
| Novo Nordisk INC | $78.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.78 | 2022 | |
| Glaxosmithkline, LLC. | $63.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $58.99 | 2022 | |
| Abbvie INC. | $50.62 | 2022 | |
| Avanir Pharmaceuticals, INC. | $47.86 | 2022 | |
| Amgen INC. | $31.93 | 2022 | |
| Philips North America LLC | $23.80 | 2022 | |
| Antares Pharma, INC. | $22.39 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.13 | 2022 | |
| Biogen, INC. | $18.96 | 2022 | |
| Pfizer INC. | $12.61 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.